News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
709,839 Results
Type
Article (40299)
Company Profile (256)
Press Release (669273)
Multimedia
Podcasts (68)
Webinars (15)
Section
Business (204417)
Career Advice (2015)
Deals (35469)
Drug Delivery (99)
Drug Development (81207)
Employer Resources (172)
FDA (16291)
Job Trends (14907)
News (345785)
Policy (32663)
Tag
Academia (2557)
Accelerated approval (14)
Adcomms (24)
Allergies (108)
Alliances (49572)
ALS (126)
Alzheimer's disease (1518)
Antibody-drug conjugate (ADC) (168)
Approvals (16342)
Artificial intelligence (355)
Autoimmune disease (39)
Automation (23)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (134)
Biotechnology (174)
Bladder cancer (111)
Brain cancer (39)
Breast cancer (411)
Cancer (3299)
Cardiovascular disease (269)
Career advice (1689)
Career pathing (32)
CAR-T (204)
CDC (37)
Cell therapy (546)
Cervical cancer (27)
Clinical research (67479)
Collaboration (1181)
Company closure (4)
Compensation (836)
Complete response letters (36)
COVID-19 (2658)
CRISPR (67)
C-suite (475)
Cystic fibrosis (120)
Data (3728)
Decentralized trials (2)
Denatured (22)
Depression (82)
Diabetes (391)
Diagnostics (6491)
Digital health (27)
Diversity (10)
Diversity, equity & inclusion (45)
Drug discovery (162)
Drug pricing (136)
Drug shortages (28)
Duchenne muscular dystrophy (170)
Earnings (88536)
Editorial (44)
Employer branding (21)
Employer resources (148)
Events (114640)
Executive appointments (889)
FDA (18433)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1048)
Gene editing (147)
Generative AI (25)
Gene therapy (430)
GLP-1 (840)
Government (4571)
Grass and pollen (5)
Guidances (331)
Healthcare (18851)
HIV (42)
Huntington's disease (32)
IgA nephropathy (47)
Immunology and inflammation (185)
Immuno-oncology (13)
Indications (45)
Infectious disease (2851)
Inflammatory bowel disease (162)
Inflation Reduction Act (10)
Influenza (77)
Intellectual property (162)
Interviews (314)
IPO (16604)
IRA (48)
Job creations (3639)
Job search strategy (1424)
Kidney cancer (13)
Labor market (64)
Layoffs (521)
Leadership (22)
Legal (7934)
Liver cancer (83)
Longevity (11)
Lung cancer (475)
Lymphoma (242)
Machine learning (22)
Management (58)
Manufacturing (508)
MASH (109)
Medical device (13560)
Medtech (13577)
Mergers & acquisitions (19670)
Metabolic disorders (952)
Multiple sclerosis (113)
NASH (16)
Neurodegenerative disease (155)
Neuropsychiatric disorders (37)
Neuroscience (2336)
NextGen: Class of 2025 (6517)
Non-profit (4492)
Now hiring (53)
Obesity (463)
Opinion (229)
Ovarian cancer (110)
Pain (138)
Pancreatic cancer (142)
Parkinson's disease (200)
Partnered (24)
Patents (366)
Patient recruitment (260)
Peanut (52)
People (58017)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20999)
Phase II (29724)
Phase III (22115)
Pipeline (2406)
Policy (230)
Postmarket research (2564)
Preclinical (8949)
Press Release (64)
Prostate cancer (164)
Psychedelics (39)
Radiopharmaceuticals (255)
Rare diseases (523)
Real estate (5927)
Recruiting (66)
Regulatory (23123)
Reports (51)
Research institute (2336)
Resumes & cover letters (350)
Rett syndrome (11)
RNA editing (11)
RSV (55)
Schizophrenia (108)
Series A (172)
Series B (131)
Service/supplier (11)
Sickle cell disease (70)
Special edition (20)
Spinal muscular atrophy (148)
Sponsored (34)
Startups (3595)
State (2)
Stomach cancer (14)
Supply chain (87)
Tariffs (72)
The Weekly (44)
Vaccines (861)
Venture capital (59)
Weight loss (291)
Women's health (51)
Worklife (17)
Date
Today (180)
Last 7 days (494)
Last 30 days (2264)
Last 365 days (30874)
2025 (21738)
2024 (35217)
2023 (40076)
2022 (51174)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (724)
Alabama (69)
Alaska (7)
Arizona (261)
Arkansas (13)
Asia (38463)
Australia (6272)
California (8561)
Canada (2647)
China (776)
Colorado (358)
Connecticut (367)
Delaware (226)
Europe (82785)
Florida (1277)
Georgia (287)
Hawaii (2)
Idaho (60)
Illinois (681)
India (40)
Indiana (405)
Iowa (17)
Japan (260)
Kansas (116)
Kentucky (31)
Louisiana (16)
Maine (65)
Maryland (1136)
Massachusetts (6262)
Michigan (266)
Minnesota (504)
Mississippi (4)
Missouri (101)
Montana (28)
Nebraska (25)
Nevada (98)
New Hampshire (68)
New Jersey (2337)
New Mexico (28)
New York (2329)
North Carolina (1195)
North Dakota (8)
Northern California (3885)
Ohio (261)
Oklahoma (17)
Oregon (35)
Pennsylvania (1807)
Puerto Rico (17)
Rhode Island (41)
South America (1099)
South Carolina (43)
South Dakota (1)
Southern California (3289)
Tennessee (138)
Texas (1320)
United States (31168)
Utah (253)
Virginia (210)
Washington D.C. (75)
Washington State (711)
West Virginia (4)
Wisconsin (72)
709,839 Results for "tyme inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
TYME Technologies, Inc. Announces Changes to its Board of Directors
TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced changes to its Board of Directors.
March 25, 2022
·
8 min read
Deals
Syros and Tyme Technologies Announce Stockholder Approval of Merger
Syros Pharmaceuticals, Inc., a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022.
September 15, 2022
·
11 min read
Business
TYME Technologies, Inc. Announces Exploration of Strategic Options
TYME Technologies, Inc., an emerging biotechnology company developing cancer metabolism-based therapies, announced that its Board of Directors has decided to explore potential strategic options to enhance stockholder value.
March 29, 2022
·
6 min read
Deals
Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its merger with Tyme Technologies, Inc., pursuant to which Syros acquired TYME, including its pipeline assets and net cash at closing of approximately $60 million.
September 16, 2022
·
9 min read
Business
TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results
TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its third fiscal quarter ended December 31, 2021.
February 11, 2022
·
15 min read
Business
TYME Technologies, Inc. Reports Fourth Fiscal Quarter and Full Year 2022 Financial and Operating Results-- $84.0 million in cash and marketable securities as of March 31, 2022 --
TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its fourth fiscal quarter and full year ended March 31, 2022.
May 25, 2022
·
10 min read
Business
TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET
TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET.
January 27, 2022
·
2 min read
Pharm Country
TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer
TYME Technologies, Inc. today announced the discontinuation of SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer.
January 26, 2022
·
8 min read
Drug Development
TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections
TYME-19 demonstrated an antiviral effect against SARS CoV-2 in human lung epithelial cells, a model frequently used for drug screening for antiviral efficacy.
December 14, 2021
·
9 min read
Pharm Country
TYME Technologies, Inc. to Present at H.C. Wainwright Bioconnect Virtual Conference - Jan 03, 2022
TYME Technologies, Inc. announced that Richie Cunningham, Chief Executive Officer, and Jonathan Eckard, Chief Business Officer, will present at the H.C. Wainwright Bioconnect Virtual Conference as follows.
January 3, 2022
·
2 min read
1 of 70,984
Next
